Clinical Trials Logo
  1. Home
  2. Acute Myeloblastic Leukemia
  3. NCT01966497

Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia — ALFA1200  

Acute Myeloblastic Leukemia Clinical Trial

Official title:
Observational Study of Patients Older Than 60 Years and With Acute Myeloblastic Leukemia Who Are Administered Standard Chemotherapy Based on Idarubicine-cytarabine

Clinical Trial Summary

The main objective of this observational survey is to estimate the incidence, the typology, and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old. In this age group (aged more than 60y), three groups of patients with very different response rates and late outcome can be delineated with specific standard chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01966497
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Hervé Dombret, MD PhD
Phone 33 1 4249 49 49
Email herve.dombret@sls.aphp.fr
Status Recruiting
Phase N/A
Start date November 2012
Completion date November 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT01041040 - LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Phase 4
Completed NCT00552825 - Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children N/A
Active, not recruiting NCT01457885 - Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Phase 2
Completed NCT04082286 - Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia Phase 1
Completed NCT01611116 - Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia Phase 2
Completed NCT00504920 - Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients N/A
Completed NCT00354120 - Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Phase 2/Phase 3
Completed NCT03280290 - Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft N/A
Completed NCT01435343 - Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia Phase 1/Phase 2
Completed NCT00487448 - SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Phase 4
Recruiting NCT05499611 - Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia
Completed NCT00390715 - Treatment of Acute Myeloblastic Leukemia in Younger Patients Phase 4
Completed NCT05696457 - Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT N/A
Recruiting NCT01296178 - PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years N/A
Active, not recruiting NCT01307241 - RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML N/A
Completed NCT00435864 - Natural Killer Index From Hematopoietic Stem Cell Graft N/A